Neuroscientific Biopharmaceuticals Ltd has released a press release.
Update on Pivotal Ocular Safety Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Appendix 4C - quarterly
- Manufacturing Update
- Key Executive Appointments to Support Clinical Studies
- NSB to investigate treatment for post-COVID Fibrosis
- Strategic Placement to AlphaSwiss Partners
Later from Neuroscientific Biopharmaceuticals
- R&D Tax Rebate Received
- NSB partners with Linear Research for Phase I Clinical Study
- Successful completion of pivotal ocular safety study
- Quarterly Update and Appendix 4C
- Results from Pulmonary Studies
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals